Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02443324 · ClinicalTrials.gov registry record · Phase 1
A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 175
- Enrollment target
NCT02443324: Completed Phase 1 study, sponsored by Eli Lilly and Company.
NCT02443324 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 175 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (192% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02443324, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 175 participants
- Enrollment target
Study Summary
The main purpose of this study is to evaluate the safety and preliminary efficacy of the combination of the study drug known as ramucirumab plus pembrolizumab in participants with locally advanced and unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma, non-small cell lung cancer (NSCLC), transitional cell carcinoma of the urothelium, or biliary tract cancer (BTC).
Primary Outcome
DLT is defined as an Adverse Event (AE) that is likely related to study medication or combination,and fulfills any one of following criteria:Common Terminology Criteria for Adverse Events (CTCAE, Version 4.0): Grade (Gr) 3 and 4 nonlaboratory toxicity (tox),Any Gr 3 or 4 laboratory value if medical intervention is required to treat participant (pt) or abnormality persists for \>1 week;Hematologic tox:Gr 4 toxicity lasting ≥ 7 days,or Gr 3 thrombocytopenia if associated with bleeding and requires
Interventions
- DRUG Pembrolizumab
- DRUG Ramucirumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 175 participants |
| Start Date | 2015-07-29 |
| Est. Completion | 2022-04-12 |
| Phase | Phase 1 |
What the finished NCT02443324 record still lists
NCT02443324 is an interventional study that assigns participants to a tested intervention. The registered 175 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (192% higher).
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT02443324 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02443324 about?
NCT02443324 is a clinical study titled "A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer". The main purpose of this study is to evaluate the safety and preliminary efficacy of the combination of the study drug known as ramucirumab plus pembrolizumab in participants with locally advanced and unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma, non-small cel...
What is the current status of trial NCT02443324?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 175 participants. The study started on 2015-07-29. Estimated completion is 2022-04-12.
What interventions are being tested in trial NCT02443324?
The interventions under investigation include: Pembrolizumab (DRUG), Ramucirumab (DRUG).
Who is sponsoring clinical trial NCT02443324?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02443324's enrollment target sits among peer trials
175 319th of 2000 higher than 1,679 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04722341 · 175 participants · NA
Time-Restricted Eating and Cancer: Clinical Outcomes, Mechanisms, and Moderators
- NCT05094037 · 175 participants · NA
Orthotic Treatment of Diabetic Foot Ulcers
- NCT05165745 · 175 participants · NA
Stick2PrEP Cisgender Women and Trans Individuals
- NCT05312255 · 175 participants · NA
Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI